Homepage > Company > Media > Pharma News > 2018 > Lupin launches generic Ancobon

Lupin launches generic Ancobon

Lupin has added to its generics lineup with its version of Valeant Pharmaceuticals’ Ancobon (flucytosine) capsules. The drug is indicated to treat serious infections caused by candida and/or Cryptococcus.

ChemSpider 2D Image | Flucytosine | C4H4FN3O

The product will be available from Lupin in 250- and 500-mg dosage strengths. These dosage strengths had U.S. sales of roughly $48 million for the 12 months ended October 2017, according to IQVIA data.

January 8, 2018

http://www.drugstorenews.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...